JPWO2023163094A1 - - Google Patents

Info

Publication number
JPWO2023163094A1
JPWO2023163094A1 JP2024503250A JP2024503250A JPWO2023163094A1 JP WO2023163094 A1 JPWO2023163094 A1 JP WO2023163094A1 JP 2024503250 A JP2024503250 A JP 2024503250A JP 2024503250 A JP2024503250 A JP 2024503250A JP WO2023163094 A1 JPWO2023163094 A1 JP WO2023163094A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024503250A
Other languages
Japanese (ja)
Other versions
JPWO2023163094A5 (https=
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2023163094A1 publication Critical patent/JPWO2023163094A1/ja
Publication of JPWO2023163094A5 publication Critical patent/JPWO2023163094A5/ja
Priority to JP2025147367A priority Critical patent/JP2025172927A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024503250A 2022-02-25 2023-02-24 Pending JPWO2023163094A1 (https=)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025147367A JP2025172927A (ja) 2022-02-25 2025-09-05 成人ｔ細胞白血病の治療又は予防のための医薬組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022027480 2022-02-25
PCT/JP2023/006691 WO2023163094A1 (ja) 2022-02-25 2023-02-24 成人ｔ細胞白血病の治療又は予防のための医薬組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025147367A Division JP2025172927A (ja) 2022-02-25 2025-09-05 成人ｔ細胞白血病の治療又は予防のための医薬組成物

Publications (2)

Publication Number Publication Date
JPWO2023163094A1 true JPWO2023163094A1 (https=) 2023-08-31
JPWO2023163094A5 JPWO2023163094A5 (https=) 2024-10-22

Family

ID=87766096

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024503250A Pending JPWO2023163094A1 (https=) 2022-02-25 2023-02-24
JP2025147367A Pending JP2025172927A (ja) 2022-02-25 2025-09-05 成人ｔ細胞白血病の治療又は予防のための医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025147367A Pending JP2025172927A (ja) 2022-02-25 2025-09-05 成人ｔ細胞白血病の治療又は予防のための医薬組成物

Country Status (5)

Country Link
US (1) US20250236642A1 (https=)
EP (1) EP4483894A4 (https=)
JP (2) JPWO2023163094A1 (https=)
CN (1) CN118678966A (https=)
WO (1) WO2023163094A1 (https=)

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002014557A1 (en) * 2000-08-15 2002-02-21 The Johns Hopkins University School Of Medecine Diagnosis and treatment of tumor-suppressor associated disorders
JP2004507445A (ja) * 2000-02-04 2004-03-11 ライデイ　ブルース　ダブリュ． 白血病、リンパ腫、及び充実性腫瘍のための温熱療法及び免疫療法
WO2006035681A1 (ja) * 2004-09-27 2006-04-06 National University Corporation Tokyo Medical And Dental University ＨＬＡ－Ａ１１拘束性Ｔａｘ抗腫瘍エピトープ
JP2007186492A (ja) * 2005-09-13 2007-07-26 Japan Health Science Foundation がんの診断、処置および／または予防、および／または浸潤・転移の抑制のための方法、システムおよび組成物ならびに関連するスクリーニング方法
WO2008026010A1 (en) * 2006-08-29 2008-03-06 Oxford Genome Sciences (Uk) Ltd Identification of protein associated with hepatocellular carcinoma, glioblastoma and lung cancer
GB2455634A (en) * 2007-12-20 2009-06-24 Ucb Pharma Sa Treatment of cancer
JP2012519492A (ja) * 2009-03-05 2012-08-30 メダレク， インコーポレイテッド Ｃａｄｍ１に特異的な完全ヒト抗体
WO2016056596A1 (ja) * 2014-10-07 2016-04-14 日本電気株式会社 Ｈｓｐ７０由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法
WO2016143814A1 (ja) * 2015-03-09 2016-09-15 日本電気株式会社 Ｍｕｃ１由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法
WO2016143816A1 (ja) * 2015-03-09 2016-09-15 日本電気株式会社 Ｇｐｃ３由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法
WO2022244801A1 (ja) * 2021-05-19 2022-11-24 国立研究開発法人医薬基盤・健康・栄養研究所 Ｈｔｌｖ－１核酸脂質粒子ワクチン

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08151396A (ja) 1994-11-28 1996-06-11 Teijin Ltd Ｈｌａ結合性オリゴペプチド及びそれを含有する免疫調節剤
WO2004092373A1 (ja) * 2003-04-16 2004-10-28 Japan Science And Technology Agency Ｈｔｌｖ－ｉ特異的ｃｔｌ誘導活性ペプチド
WO2006004182A1 (ja) 2004-07-07 2006-01-12 Nec Corporation 配列予測システム
WO2012119989A2 (en) * 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
JP5999703B2 (ja) * 2013-01-09 2016-09-28 国立大学法人 東京医科歯科大学 ＨＬＡ−ＤＲ１拘束性Ｔａｘ特異的ＣＤ４＋Ｔ細胞エピトープ
CN109535231B (zh) * 2018-11-21 2021-03-19 温州医科大学附属第一医院 人T细胞病毒抗原蛋白Tax的CTL特异性识别表位及其应用
JP7593242B2 (ja) 2020-07-29 2024-12-03 Jsr株式会社 液晶配向剤、液晶配向膜及び液晶素子

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004507445A (ja) * 2000-02-04 2004-03-11 ライデイ　ブルース　ダブリュ． 白血病、リンパ腫、及び充実性腫瘍のための温熱療法及び免疫療法
WO2002014557A1 (en) * 2000-08-15 2002-02-21 The Johns Hopkins University School Of Medecine Diagnosis and treatment of tumor-suppressor associated disorders
WO2006035681A1 (ja) * 2004-09-27 2006-04-06 National University Corporation Tokyo Medical And Dental University ＨＬＡ－Ａ１１拘束性Ｔａｘ抗腫瘍エピトープ
JP2007186492A (ja) * 2005-09-13 2007-07-26 Japan Health Science Foundation がんの診断、処置および／または予防、および／または浸潤・転移の抑制のための方法、システムおよび組成物ならびに関連するスクリーニング方法
WO2008026010A1 (en) * 2006-08-29 2008-03-06 Oxford Genome Sciences (Uk) Ltd Identification of protein associated with hepatocellular carcinoma, glioblastoma and lung cancer
GB2455634A (en) * 2007-12-20 2009-06-24 Ucb Pharma Sa Treatment of cancer
JP2012519492A (ja) * 2009-03-05 2012-08-30 メダレク， インコーポレイテッド Ｃａｄｍ１に特異的な完全ヒト抗体
WO2016056596A1 (ja) * 2014-10-07 2016-04-14 日本電気株式会社 Ｈｓｐ７０由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法
WO2016143814A1 (ja) * 2015-03-09 2016-09-15 日本電気株式会社 Ｍｕｃ１由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法
WO2016143816A1 (ja) * 2015-03-09 2016-09-15 日本電気株式会社 Ｇｐｃ３由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法
WO2022244801A1 (ja) * 2021-05-19 2022-11-24 国立研究開発法人医薬基盤・健康・栄養研究所 Ｈｔｌｖ－１核酸脂質粒子ワクチン

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"成人Ｔ 細胞性白血病に対する新規複合的ワクチン療法の治験を開始−国内初の自家細胞加工製品−", 九州大学ＰＲＥＳＳ ＲＥＬＥＡＳＥ, JPN6025027384, 2015, ISSN: 0005637849 *
CHILMI, S. ET AL.: "Development of anti-human CADM1 monoclonal antibodies as a potential therapy for adult T-cell leukem", INTERNATIONAL JOURNAL OF HEMATOLOGY, vol. 112, JPN6022024730, 2020, pages 496 - 503, ISSN: 0005744695 *

Also Published As

Publication number Publication date
US20250236642A1 (en) 2025-07-24
EP4483894A4 (en) 2026-04-29
EP4483894A1 (en) 2025-01-01
JP2025172927A (ja) 2025-11-26
WO2023163094A1 (ja) 2023-08-31
CN118678966A (zh) 2024-09-20

Similar Documents

Publication Publication Date Title
BR102022025291A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
JPWO2023163094A1 (https=)
BR102023001987A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR102022023461A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
CN307046237S (https=)
BY13138U (https=)
CN307049578S (https=)
CN307048445S (https=)
CN307048243S (https=)
CN307047611S (https=)
CN307047446S (https=)
CN307050104S (https=)
BY13142U (https=)
CN307046496S (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240816

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240816

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20241219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250708

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251202